538P - First report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Biomarkers
Colon Cancer
Rectal Cancer
Presenter Osamu Muto
Citation Annals of Oncology (2014) 25 (suppl_4): iv167-iv209. 10.1093/annonc/mdu333
Authors O. Muto1, S. Yuki2, .3, M. Nakamura4, A. Hosokawa5, T. Kato6, I. Iwanaga7, K. Hatanaka8, Y. Tsuji9, A. Sato10, K. Eto11, K. Furukawa12, H. Okuda13, M. Onodera14, K. Fujikawa15, M. Kudo16, S. Yokoyama17, T. Honda18, Y. Sakata19, Y. Komatsu3
  • 1Medical Oncology, Japanese Red Cross Akita Hospital, 010-1406 - Akita/JP
  • 2Gastroenterology And Hepatology, Hokkaido University Hospital, 064-0804 - Sapporo/JP
  • 3Cancer Center, Hokkaido University Hospital, Sapporo/JP
  • 4Gastroenterology, Sapporo City General Hospital, Sapporo/JP
  • 5Gastroenterology And Hematology, University of Toyama, 930-0194 - Toyama/JP
  • 6Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo/JP
  • 7Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami/JP
  • 8Gastroenterology, Hakodate Municipal Hospital, 041-8680 - Hakodate/JP
  • 9Medical Oncology, Tonan Hospital, Sapporo/JP
  • 10Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki/JP
  • 11Gastroenterology, Tomakomai City Hospital, Tomakomai/JP
  • 12Gastroenterology, Niigata City General Hospital, Niigata/JP
  • 13Medical Oncology, Keiyukai Sapporo Hospital, Sapporo/JP
  • 14Gastroenterology, Abashiri Kosei General Hospital, Abashiri/JP
  • 15Gastroenterology, Hokkaido Cancer Center, Sapporo/JP
  • 16Gastroenterology, Sapporo Hokuyu Hospital, Sapporo/JP
  • 17Surgery, Kumamoto City Hospital, Kumamoto/JP
  • 18Gastroenterology And Hepatology, Nagasaki University Graduate School of Biomedical Science, Nagasaki/JP
  • 19Ceo, Misawa City Hospital, JP-033-0022 - Misawa/JP

Abstract

Aim

IRIS is one of the standard regimens as second line treatment in mCRC since IRIS demonstrated the non-inferiority to FOLFIRI (FIRIS study) in Japan. From the results of 20050181 trial, FOLFIRI/panitumumab significantly improved PFS and is well-tolerated as second-line treatment in patients with KRAS wild type of mCRC. Thus we conduct the study of IRIS/Cet (HGCSG0902).

Methods

HGSCG0902 is a multicenter phase ll study. Eligibility includes histologically confirmed colorectal cancer, previously received oxaliplatin-contained chemotherapy, PS: 0-1, EGFR positive and KRAS Exon2 wild type. Patients (pts) received S-1 80-120 mg/day p.o. on days 1-14 and irinotecan 100mg/m2 on days 1 and 15 repeated every 28 days. Cetuximab was administrated 400mg/m2 loading dose and continued 250mg/m2 every week or 500mg/m2 bi-weekly. The primary endpoint was response rate and the secondary endpoints were disease control rate, PFS, OS and safety. We estimated that a target sample size of 76 patients.

Results

Between Mar 2010 and September 2013, 58 pts were enrolled. One patient was not administered (57 pts were safety analysis set), and 3 pts were ineligible (54 pts were efficacy analysis set). Patients characteristics were as follows: median age 66 years (range 35-79), Male: female 36:21, PS 0:1 38:19. Median number of cycles was 3. The main grade 3-4 AE were diarrhea (35.1%), neutropenia (26.8%), acne like rash (17.5%) and anorexia (15.8%). The median relative dose intensity of IRIS/Cet was 0.818. Response rate was 33.3% (95%CI 20.8-45.9%) and disease control rate was 79.6%. Median progression-free survival was 4.7 months (95%C.I. 3.3-6.1 months).

Conclusions

IRIS/Cet appeared to be highly effective with a response rate of 33.3% and progression-free survival of 4.7 months, and had met the primary endpoint. Diarrhea was a major adverse event, but was manageable by dose reduction and supportive care. The final analysis will be presented in 2015 ASCO Annual meeting.

Disclosure

S. Yuki: Taiho Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, Merck Serono, Takeda Pharmaceutical, Yakult Honsha;M. Nakamura: Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin;Y. Tsuji: Honoraria - Ono Pharmaceutical; Y. Sakata: Taiho Pharmaceutical, Daiichi Sankyo, Yakult Honsha, Otsuka Pharmaceutical, Merck Serono, Bristol-Myers Squibb, Synergy International; Y. Komatsu: Yakult Honsha, Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Pfizer Japan, Novartis Pharma, Sawai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Eli Lilly Japan, Kureha Corporation. All other authors have declared no conflicts of interest.